Impact of COVID-19 In-hospital Mortality in Chagas Disease Patients
- PMID: 35615087
- PMCID: PMC9125174
- DOI: 10.3389/fmed.2022.880796
Impact of COVID-19 In-hospital Mortality in Chagas Disease Patients
Erratum in
-
Corrigendum: Impact of COVID-19 in-hospital mortality in chagas disease patients.Front Med (Lausanne). 2022 Jul 26;9:963805. doi: 10.3389/fmed.2022.963805. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35957851 Free PMC article.
Abstract
The COVID-19 virus infection caused by the new SARS-CoV-2 was first identified in Rio de Janeiro (RJ), Brazil, in March 2020. Until the end of 2021, 504,399 COVID-19 cases were confirmed in RJ, and the total death toll reached 68,347. The Evandro Chagas National Institute of Infectious Diseases from Oswaldo Cruz Foundation (INI-Fiocruz) is a referral center for treatment and research of several infectious diseases, including COVID-19 and Chagas disease (CD). The present study aimed to evaluate the impact of COVID-19 on in-hospital mortality of patients with CD during the COVID-19 pandemic period. This observational, retrospective, longitudinal study evaluated all patients with CD hospitalized at INI-Fiocruz from May 1, 2020, to November 30, 2021. One hundred ten hospitalizations from 81 patients with CD (58% women; 68 ± 11 years) were evaluated. Death was the study's main outcome, which occurred in 20 cases. The mixed-effects logistic regression was performed with the following variables to test whether patients admitted to the hospital with a COVID-19 diagnosis would be more likely to die than those admitted with other diagnoses: admission diagnosis, sex, age, COVID-19 vaccination status, CD clinical classification, and the number of comorbidities. Results from multiple logistic regression analysis showed a higher risk of in-hospital mortality in patients diagnosed with COVID-19 (OR 6.37; 95% CI 1.78-22.86) compared to other causes of admissions. In conclusion, COVID-19 infection had a significant impact on the mortality risk of INI-Fiocruz CD patients, accounting for one-third of deaths overall. COVID-19 presented the highest percentage of death significantly higher than those admitted due to other causes during the COVID-19 pandemic.
Keywords: COVID-19; Chagas disease; SARS-CoV-2; Trypanosoma cruzi; in-hospital mortality.
Copyright © 2022 Sperandio da Silva, Mediano, Murgel, Andrade, de Holanda, Valete Rosalino, de Sousa, Mendes, Pinheiro, Veloso, Saraiva and Hasslocher-Moreno.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.EClinicalMedicine. 2020 Dec 23;31:100694. doi: 10.1016/j.eclinm.2020.100694. eCollection 2021 Jan. EClinicalMedicine. 2020. PMID: 33554085 Free PMC article.
-
Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data.Lancet Respir Med. 2021 Apr;9(4):407-418. doi: 10.1016/S2213-2600(20)30560-9. Epub 2021 Jan 15. Lancet Respir Med. 2021. PMID: 33460571 Free PMC article.
-
Neuroparacoccidioidomycosis: A 13-Year Cohort Study, Rio de Janeiro, Brazil.J Fungi (Basel). 2020 Nov 20;6(4):303. doi: 10.3390/jof6040303. J Fungi (Basel). 2020. PMID: 33233507 Free PMC article.
-
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study.Lancet HIV. 2021 Sep;8(9):e554-e567. doi: 10.1016/S2352-3018(21)00151-X. Epub 2021 Aug 4. Lancet HIV. 2021. PMID: 34363789 Free PMC article.
-
Comment on: Electrocardiographic findings and mortality in covid-19 patients hospitalized in different clinical settings.Curr Probl Cardiol. 2023 Jul 1:101893. doi: 10.1016/j.cpcardiol.2023.101893. Online ahead of print. Curr Probl Cardiol. 2023. PMID: 37399861 Review.
Cited by
-
Re: "Challenges of addressing neglected tropical diseases amidst the COVID-19 pandemic in Africa: A case of Chagas Disease".Ann Med Surg (Lond). 2022 Nov;83:104804. doi: 10.1016/j.amsu.2022.104804. Epub 2022 Oct 31. Ann Med Surg (Lond). 2022. PMID: 36339921 Free PMC article. No abstract available.
-
Impact of COVID-19 on the incidence of visceral leishmaniasis in children and adolescents in the Northeast region, 2007-2022: time series study.Epidemiol Serv Saude. 2025 Jun 13;34:e20240382. doi: 10.1590/S2237-96222025v34e20240382.en. eCollection 2025. Epidemiol Serv Saude. 2025. PMID: 40531712 Free PMC article.
-
Hospital case fatality and mortality related to Chagas disease in Brazil over two decades.BMC Public Health. 2024 Aug 22;24(1):2282. doi: 10.1186/s12889-024-19618-z. BMC Public Health. 2024. PMID: 39174935 Free PMC article.
-
Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study.Rev Inst Med Trop Sao Paulo. 2024 Dec 16;66:e73. doi: 10.1590/S1678-9946202466073. eCollection 2024. Rev Inst Med Trop Sao Paulo. 2024. PMID: 39699511 Free PMC article.
References
-
- World Health Organization . Global Distribution of Cases of Chagas Disease Based on Official Estimates, 2018. World Health Organization (2018). Available online at: https://www.who.int/docs/default-source/ntds/chagas-disease/chagas-2018-... (accessed April 13, 2022).
-
- World Health Organization (WHO) . Archived: WHO Timeline - COVID-19. (2020). Available online at: https://www.who.int/news/item/27-04-2020-who-timeline—covid-19 (accessed January 29, 2022).
-
- Ministerio da Saúde do Brasil . Painel Coronavírus. (2022). Available online at: https://covid.saude.gov.br/ (accessed January 28, 2022).
LinkOut - more resources
Full Text Sources
Miscellaneous